Eli Lilly’s leadership in GLP-1 weight-loss drugs has made the company a standout in healthcare investing, but the concentration of its revenue stream is drawing fresh scrutiny from market participants. Data cited from recent quarterly results show that GLP-1 products are still driving the bulk of sales—an outcome that can boost momentum in the near term while also raising questions about durability as competitive dynamics and growth rates evolve.
Investors are also weighing how quickly GLP-1 growth could normalize and whether Lilly can translate today’s weight-loss success into a broader pipeline through acquisitions and expanded indications. The debate matters because the market’s expectations for growth are increasingly tied to the pace of demand and the company’s ability to sustain innovation beyond its current flagship franchise.
Key takeaways
- Revenue concentration remains central: In the cited quarter, GLP-1 products accounted for nearly two-thirds of Eli Lilly’s total revenue.
- Growth momentum is strong but may be moderating: The growth rate cited for Zepbound appears lower in the later comparison period than earlier.
- New products are contributing: The introduction of the Foundayo GLP-1 pill began generating revenue in the quarter.
- Implication for investors: The investment case increasingly hinges on whether Lilly can maintain GLP-1 share and fund expansion into new treatment areas without a slowdown in earnings growth.
What’s driving the focus on Lilly’s GLP-1 franchise
According to the article’s figures, sales of Mounjaro rose 91% year over year in the second quarter of 2026, while Zepbound sales increased 46% year over year. The report also said that Foundayo, a newly introduced GLP-1 pill, started generating revenue during the quarter.
Combined, the cited GLP-1 weight-loss drugs generated nearly $15 billion out of roughly $23 billion in total revenue for the quarter—about two-thirds of the company’s top line. For investors, the immediate takeaway is straightforward: the company’s financial performance remains highly levered to the demand trajectory for GLP-1 medications.
That leverage can be beneficial when uptake is accelerating and manufacturing and supply are keeping pace with demand. But it can also magnify downside if competitive pressure intensifies, pricing dynamics change, or incremental demand slows.
Is GLP-1 growth peaking or simply normalizing?
The article argues that as a business scales, maintaining very high growth rates becomes harder over time. It pointed to changes in Zepbound’s year-over-year expansion: Zepbound sales reportedly grew 172% in the second quarter of 2025, compared with 46% growth in the second quarter of 2026.
While the report notes that Mounjaro’s growth accelerated—from 68% in the earlier comparison to 91% in the later period—Lilly’s overall GLP-1 growth profile still appears sensitive to product-by-product demand trends. In practical terms for investors, this means the market may scrutinize not only total GLP-1 revenue, but also the mix between brands and the trajectory of incremental growth.
If growth moderates, the earnings narrative could shift from “rapid expansion” to “sustaining scale with tighter operating assumptions,” which typically changes valuation support. Conversely, evidence of sustained acceleration in one major product—such as the reported strength in Mounjaro—can help offset slower growth elsewhere, but it may not fully remove the market’s concern about longer-term growth rates.
How Lilly is positioning for life beyond weight loss
Beyond the near-term GLP-1 franchise, the article says Lilly has been using its GLP-1 success to fund acquisitions aimed at expanding into new treatment areas. The implication is that management is trying to reduce reliance on weight-loss indications by broadening the company’s therapeutic scope.
That strategy carries both potential upside and execution risk. Expanding beyond a core franchise can create multiple growth engines, but the report highlights a key challenge: developing and integrating new treatments can be time-consuming, difficult, and uncertain in outcomes. Even if acquisitions broaden the pipeline, investors will still focus on whether those assets produce credible clinical progress and translate into future commercial revenue.
In the current context, Lilly’s ability to fund expansion also depends on the health of its GLP-1 cash flows. If growth slows materially, the pace of business-building efforts could face tougher trade-offs—even if management remains committed to using surplus capital for expansion.
What analysts and investors may focus on next
Based on the article’s framing, three big factors are likely to remain in focus: the size of the GLP-1 business, the rate at which GLP-1 demand is expanding, and progress toward expanding beyond the weight-loss market. If investors concentrate only on current success without tracking growth normalization and pipeline development, they may be surprised by changes in the forward narrative.
Investors watching Lilly going forward may want to track updates that show whether growth rates stabilize at a new level, how new products like Foundayo contribute to the revenue mix, and whether acquisitions expand the pipeline in a way that improves the company’s longer-term earnings visibility.
For the next phase, the key watchpoints are the company’s subsequent quarterly updates on GLP-1 sales momentum and any disclosures around expansion initiatives, including the commercial progress of new products and the operational results of M&A activity. Market attention will likely sharpen around upcoming data releases and management commentary that clarify how quickly GLP-1 growth is evolving and what that means for the broader strategy to diversify beyond weight loss.
